i
Interim Estimates of Vaccine Effectiveness of Pfizer-BioNTech and Moderna Covid-19 Vaccines Among Health Care Personnel — 33 U.S. Sites, January–March 2021
-
May 21 2021
-
Source: MMWR Morb Mortal Wkly Rep. 70(20):753-758
[PDF-122.43 KB]
Details:
-
Alternative Title:MMWR Morb Mortal Wkly Rep
-
Personal Author:
-
Corporate Authors:
-
Description:Throughout the COVID-19 pandemic, health care personnel (HCP) have been at high risk for exposure to SARS-CoV-2, the Virus that causes COVID-19, through patient interactions and community exposure (1). The Advisory Committee on Immunization Practices recommended prioritization of HCP for COVID-19 vaccination to maintain provision of critical services and reduce spread of infection in health care settings (2). Early distribution of two mRNA COVID-19 vaccines (Pfizer-BioNTech and Moderna) to HCP allowed assessment of the effectiveness of these vaccines in a real-world setting. A test-negative case-control study is underway to evaluate mRNA COVID-19 vaccine effectiveness (VE) against symptomatic illness among HCP at 33 U.S. sites across 25 U.S. states. Interim analyses indicated that the VE of a single dose (measured 14 days after the first dose through 6 days after the second dose) was 82% (95% confidence interval [CI] = 74%-87%), adjusted for age, race/ethnicity, and underlying medical conditions. The adjusted VE of 2 doses (measured ≥7 days after the second dose) was 94% (95% CI = 87%-97%). VE of partial (1-dose) and complete (2-dose) vaccination in this population is comparable to that reported from clinical trials and recent observational studies, supporting the effectiveness of mRNA COVID-19 vaccines against symptomatic disease in adults, with strong 2-dose protection.
-
Subjects:
-
Source:
-
Pubmed ID:34014909
-
Pubmed Central ID:PMC8136422
-
Document Type:
-
Place as Subject:
-
Volume:70
-
Issue:20
-
Collection(s):
-
Main Document Checksum:
-
Download URL:
-
File Type:
